Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
×

Get our Best Content in Your Email

You are already a member! Please enter your password to sign in.

Using laser technology to cure cancer

Stockhouse Editorial
3 Comments| September 8, 2017


Click to enlargeLasers in healthcare? It’s old news. From laser eye surgery to pain management, laser technology has already made a big impact on the healthcare industry.

Using lasers to cure cancer? That’s a different story. Laser technology has been introduced to help treat cancer, in various ways. Theralase Technologies Inc. (TSXV: TLT, OTCQX: TLTFF, Forum) is going beyond these therapies – way beyond.

The Company’s proprietary laser technology is currently being tested to not merely treat cancer, but to destroy certain forms of cancer. Here it is important to note that this research is targeting internal forms of this dreaded disease that currently provide poor options (and outcomes) for patients.

The Stockhouse audience has already been introduced to Theralase, in a feature article from April 13, 2017. That article posed the question, “Is a Trojan Horse the key to curing cancer?”

Lasers, Trojan Horses, curing cancer – pretty exciting stuff.

The important point for investors is that this is not merely theoretical. TLT has already advanced well beyond the “pre-clinical testing phase”, involving non-human test subjects. The Company is now into full clinical testing – human testing. This is the final “proof of concept” work which is necessary before obtaining regulatory approval and being able to take its potentially revolutionary technology to market.

Stockhouse recently had the opportunity to sit down with the Company’s President and CEO, Roger Dumoulin-White, to hear about the latest developments with this cutting-edge healthcare technology.

theralase.com




Get it on iTunes  Listen on Google Play Music

FULL DISCLOSURE: Theralase Technologies Inc is a paid client of Stockhouse Publishing.

Tags:

Rate this article
0 stars
v
Usefulness

Clarity

Credibility

Interested in these industries and sectors?

Receive investor kits and email updates from Stockhouse and directly from these companies.

Healthcare

Interested in these industries and sectors?

You are already a member! Please enter your password to sign in.

Comments

WatchLearnEarn
Maybe the Shlockhouse guy interviewing you can be excused for reading his presentation, but Roger, YOU KNOW THIS STUFF! Please don't read your responses. It sounds awkward and disingenuous. We've heard you discuss this technology at length in other interviews for years now with no notes. There's no reason you should be reading a pre-written cheat sheet. When written words are mis-spoken, which is inevitable when reading aloud for several minutes, it makes it seem like you don'...
1.5 stars
September 21, 2017
Rate this comment
0 stars
v
Usefulness

Clarity

Credibility

robwilly
spdt has had mixed results according to feed back found on the net; so far TLTFF is batting 100%, big difference. The PDC's used by TLTFF are the best developed, and I would not be surprised if it becomes the standard of care for MOST g.i., hollow organ, and brain cancers.
2 stars
October 24, 2017
Rate this comment
0 stars
v
Usefulness

Clarity

Credibility

richardcollins6
Canada is so far behind healthcare therapies and they do not need to waste there time on trials.get a plane ticket to Osaka Japan to saisei mirai Kehan Clinic Dr. INUI, as pdc is outdated and spdt is now happening and also HIFU. plus so many other therapies to go along with it This been going on for years and Canada is just starting to look at it.It is an absolute shame that Canada is pissing away money to bring in outdated stuff
0 stars
September 24, 2017
Rate this comment
0 stars
v
Usefulness

Clarity

Credibility

Leave a Comment

You must be logged in to access this feature.